Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2020 - 2025)

Insight Molecular Diagnostics' Net Income towards Common Stockholders history spans 6 years, with the latest figure at -$10.9 million for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders rose 19.56% year-over-year to -$10.9 million; the TTM value through Sep 2025 reached -$60.9 million, down 122.12%, while the annual FY2024 figure was -$61.0 million, 1986.16% down from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$10.9 million at Insight Molecular Diagnostics, down from -$9.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $2397.0 in Q1 2023 and bottomed at -$45.2 million in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$9.6 million (2022), against an average of -$13.4 million.
  • The largest annual shift saw Net Income towards Common Stockholders soared 100.02% in 2023 before it plummeted 389545.14% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$35.9 million in 2021, then decreased by 25.97% to -$45.2 million in 2022, then skyrocketed by 91.4% to -$3.9 million in 2023, then crashed by 765.25% to -$33.6 million in 2024, then skyrocketed by 67.72% to -$10.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Net Income towards Common Stockholders are -$10.9 million (Q3 2025), -$9.7 million (Q2 2025), and -$6.7 million (Q1 2025).